N. Özyurt Et Al. , "The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study," Scientific Reports , vol.14, no.1, 2024
Özyurt, N. Et Al. 2024. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study. Scientific Reports , vol.14, no.1 .
Özyurt, N., Alkan, A., Gülbağcı, B., Seyyar, M., AYDIN, E., Şahbazlar, M., ... Türker, M.(2024). The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study. Scientific Reports , vol.14, no.1.
Özyurt, Neslihan Et Al. "The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study," Scientific Reports , vol.14, no.1, 2024
Özyurt, Neslihan Et Al. "The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study." Scientific Reports , vol.14, no.1, 2024
Özyurt, N. Et Al. (2024) . "The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study." Scientific Reports , vol.14, no.1.
@article{article, author={Neslihan Özyurt Et Al. }, title={The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study}, journal={Scientific Reports}, year=2024}